Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Thyroid Cancer | Research article

Thyroid cancer overdiagnosis and overtreatment: a cross- sectional study at a thyroid cancer referral center in Ecuador

Authors: Paola Solis-Pazmino, Jorge Salazar-Vega, Eddy Lincango-Naranjo, Cristhian Garcia, Gabriela Jaramillo Koupermann, Esteban Ortiz-Prado, Tannya Ledesma, Tatiana Rojas, Benjamin Alvarado-Mafla, Cesar Carcamo, Oscar J. Ponce, Juan P. Brito

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

In contrast to the rapid increase in thyroid cancer incidence, the mortality has remained low and stable over the last decades. In Ecuador, however, thyroid cancer mortality has increased. The objective of this study is to determine possible drivers of high rates of thyroid cancer mortality, through a cross-sectional analysis of all patients attending a thyroid cancer referral center in Ecuador.

Methods

From June 2014 to December 2017, a cross-sectional study was conducted at the Hospital de Especialidades Eugenio Espejo, a regional reference public hospital for endocrine neoplasia in adults in Quito, Ecuador. We identified the mechanism of detection, histopathology and treatment modalities from a patient interview and review of clinical records.

Results

Among 452 patients, 74.8% were young adults and 94.2% (426) were female. 13.7% had a family history of thyroid cancer, and patients’ median tumor size was 2 cm. The incidental finding was 54.2% whereas 45.8% was non-incidental. Thyroid cancer histology reported that 93.3% had papillary thyroid cancer (PTC), 2.7% follicular, 1.5% Hurtle cells, 1.6% medullary, 0.7% poor differentiated, and 0.2% anaplastic carcinoma. The mean MACIS (metastasis, age, completeness, invasion, and size) score was 4.95 (CI 4.15–5.95) with 76.2% of the thyroid cancer patients having MACIS score less than or equal to 6. The very low and low risk of recurrence was 18.1% (79) and 62% (271) respectively. An analysis of 319 patients with non-metastatic thyroid cancer showed that 10.7% (34) of patients had surgical complications. Moreover, around 62.5% (80 from 128 patients with thyroglobulin laboratory results) of TC patients had a stimulated-thyroglobulin value equal or higher than 2 ng/ml. Overall, a poor surgical outcome was present in 35.1% (112) patients. Out of 436 patients with differentiated thyroid carcinoma, 86% (375) received radioactive iodine.

Conclusion

Thyroid cancer histological characteristics and method of diagnosis are like those described in other reports without any evidence of the high frequency of aggressive thyroid cancer histology. However, we observed evidence of overtreatment and poor surgical outcomes that demand additional studies to understand their association with thyroid cancer mortality in Ecuador.
Literature
2.
go back to reference Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJCK. SEER Cancer Statistics Review 1975–2014 National Cancer Institute SEER Cancer Statistics Review 1975–2014 National Cancer Institute; 2017. p. 2012–4. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJCK. SEER Cancer Statistics Review 1975–2014 National Cancer Institute SEER Cancer Statistics Review 1975–2014 National Cancer Institute; 2017. p. 2012–4.
9.
go back to reference La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–95.CrossRef La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–95.CrossRef
11.
go back to reference INEC. Anuario de Estadisticas vitales: Nacimientos y Defunciones. 2013. INEC. Anuario de Estadisticas vitales: Nacimientos y Defunciones. 2013.
12.
go back to reference King-yin LA. Pathology of endocrine tumors update: World Health Organization new classification 2017—other thyroid tumors. AJSP Rev Reports. 2017;22:209–16. King-yin LA. Pathology of endocrine tumors update: World Health Organization new classification 2017—other thyroid tumors. AJSP Rev Reports. 2017;22:209–16.
14.
go back to reference Pitoia F, Califano I, Vázquez A, Faure E, Gauna A, Orlandi A, et al. Consenso intersocietario∗ sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides. Rev Argent Endocrinol Metab. 2014;51:85–118. Pitoia F, Califano I, Vázquez A, Faure E, Gauna A, Orlandi A, et al. Consenso intersocietario∗ sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides. Rev Argent Endocrinol Metab. 2014;51:85–118.
18.
go back to reference Chang YW, Kim HS, Jung SP, Kim HY, Lee JB, Bae JW, et al. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio. Int J Clin Oncol. 2016;21:862–8.CrossRef Chang YW, Kim HS, Jung SP, Kim HY, Lee JB, Bae JW, et al. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio. Int J Clin Oncol. 2016;21:862–8.CrossRef
20.
go back to reference Papaleontiou M, Hughes DT, Guo C, Banerjee M, Haymart MR. Population-based assessment of complications following surgery for thyroid cancer. J Clin Endocrinol Metab. 2017;102:2543–51.CrossRef Papaleontiou M, Hughes DT, Guo C, Banerjee M, Haymart MR. Population-based assessment of complications following surgery for thyroid cancer. J Clin Endocrinol Metab. 2017;102:2543–51.CrossRef
21.
go back to reference Adam MA, Thomas S, Youngwirth L, Hyslop T, Reed SD, Scheri RP, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg. 2017;265:402–7.CrossRef Adam MA, Thomas S, Youngwirth L, Hyslop T, Reed SD, Scheri RP, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg. 2017;265:402–7.CrossRef
22.
go back to reference Liu JB, Sosa JA, Grogan RH, Liu Y, Cohen ME, Ko CY, et al. Variation of thyroidectomy-specific outcomes among hospitals and their association with risk adjustment and hospital performance. JAMA Surg. 2018;153:1–10.CrossRef Liu JB, Sosa JA, Grogan RH, Liu Y, Cohen ME, Ko CY, et al. Variation of thyroidectomy-specific outcomes among hospitals and their association with risk adjustment and hospital performance. JAMA Surg. 2018;153:1–10.CrossRef
23.
go back to reference Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:1–13.CrossRef Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:1–13.CrossRef
28.
go back to reference Russo Picasso MF, Vicens J, Giuliani C, Jaén ADV, Cabezón C, Figari M, et al. Role of the mechanisms of detection in the increased risk of thyroid Cancer: a retrospective cohort study in an HMO in Buenos Aires. J Cancer Epidemiol. 2018;2018. Russo Picasso MF, Vicens J, Giuliani C, Jaén ADV, Cabezón C, Figari M, et al. Role of the mechanisms of detection in the increased risk of thyroid Cancer: a retrospective cohort study in an HMO in Buenos Aires. J Cancer Epidemiol. 2018;2018.
36.
go back to reference Li M, Maso LD, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8:468–70.CrossRef Li M, Maso LD, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8:468–70.CrossRef
37.
go back to reference Haymart MR, Banerjee M, Reyes-Gastelum D, Caoili E, Norton EC. Thyroid ultrasound and the increase in diagnosis of low-risk thyroid Cancer. J Clin Endocrinol Metab. 2018;104:785–92.CrossRef Haymart MR, Banerjee M, Reyes-Gastelum D, Caoili E, Norton EC. Thyroid ultrasound and the increase in diagnosis of low-risk thyroid Cancer. J Clin Endocrinol Metab. 2018;104:785–92.CrossRef
43.
go back to reference Metter D, Phillips WT, Walker RC, Blumhardt R. To use or not to use 131I in thyroid cancer. Clin Nucl Med. 2018;43:670–1.CrossRef Metter D, Phillips WT, Walker RC, Blumhardt R. To use or not to use 131I in thyroid cancer. Clin Nucl Med. 2018;43:670–1.CrossRef
44.
go back to reference Michael Tuttle R, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of 131 I therapy in differentiated thyroid Cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular . 2019. Michael Tuttle R, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of 131 I therapy in differentiated thyroid Cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular . 2019.
Metadata
Title
Thyroid cancer overdiagnosis and overtreatment: a cross- sectional study at a thyroid cancer referral center in Ecuador
Authors
Paola Solis-Pazmino
Jorge Salazar-Vega
Eddy Lincango-Naranjo
Cristhian Garcia
Gabriela Jaramillo Koupermann
Esteban Ortiz-Prado
Tannya Ledesma
Tatiana Rojas
Benjamin Alvarado-Mafla
Cesar Carcamo
Oscar J. Ponce
Juan P. Brito
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07735-y

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine